×

FcgammaRIIB-specific Fc region variant

  • US 10,919,953 B2
  • Filed: 08/23/2013
  • Issued: 02/16/2021
  • Est. Priority Date: 08/24/2012
  • Status: Active Grant
First Claim
Patent Images

1. A protein comprising an IgG Fc region variant in which the amino acid at position 238 (EU numbering) is Asp, wherein the IgG Fc region variant further comprises one of the following combinations (i) to (xxiv) (all positions by EU numbering):

  • (i) Asp at position 233, Asp at position 237, Asp at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;

    (ii) Asp at position 237, Asp or Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;

    (iii) Asp at position 233, Asp at position 237, Asp at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Thr at position 332;

    (iv) Asp at position 233, Asp at position 237, Ile at position 264, Gly or Ala at position 267, Glu at position 268, Gly at position 271, and Arg at position 330;

    (v) Asp at position 233, Asp at position 237, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Thr at position 332;

    (vi) Asp at position 237, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Thr at position 332;

    (vii) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, and Gly at position 271;

    (viii) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;

    (ix) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Met or Leu at position 396;

    (x) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, and Arg at position 330;

    (xi) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;

    (xii) Ile at position 264, Ala at position 267, Glu at position 268, and Gly at position 271;

    (xiii) Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, and Asp at position 296;

    (xiv) Asp at position 237, Ala or Gly at position 267, Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;

    (xv) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Arg at position 330, and Met or Leu at position 396;

    (xvi) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Gly at position 327, Arg at position 330, and Met at position 396;

    (xvii) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 272, and Asp at position 296;

    (xviii) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Pro at position 272, and Arg at position 330;

    (xix) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Pro at position 272, Asp at position 296, and Arg at position 330;

    (xx) Asp at position 233, Ile at position 264, Ala at position 267, Glu at position 268, and Gly at position 271;

    (xxi) Asp at position 237, Gly at position 267, Asp at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;

    (xxii) Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 272, Asp at position 296;

    (xxiii) Asp at position 233, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, and Asp at position 296;

    or(xxiv) Asp at position 233, Tyr at position 234, Phe at position 235, Asp at position 237, Ile at position 264, Glu at position 265, Phe at position 266, Ala at position 267, Asp at position 268, Asp at position 269, Gly at position 271, Asp at position 272, Gln at position 274, Asp at position 296, Ala at position 326, Gly at position 327, Lys at position 330, Ser at position 331, Lys at position 332, Lys at position 333, Arg at position 334, Ala at position 355, Glu at position 356, Met at position 358, Ala at position 396, Arg at position 409, and Glu at position 419.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×